Nebivolol Krka (Nebivolol)

Nebivolol is a selective β1‑adrenergic antagonist used primarily in the management of hypertension.

• Hypertension: lowers systolic and diastolic blood pressure, helping to reduce the risk of cardiovascular events.

• Nebivolol selectively blocks β1‑adrenergic receptors in cardiac tissue, which diminishes heart rate and myocardial contractility. In addition, it stimulates endothelial nitric‑oxide synthase, leading to nitric‑oxide mediated vasodilation and a reduction in peripheral vascular resistance, thereby contributing to blood‑pressure control.

Nebivolol may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects

• Fatigue: mild to moderate tiredness reported by patients.
• Headache: occasional throbbing pain.
• Dizziness: especially on standing.
• Bradycardia: slower than normal heart rate.
• Nausea: mild gastrointestinal upset.
• Peripheral edema: swelling of ankles or feet.

Serious or Rare Side Effects

• Severe bradycardia: heart rate dropping to dangerously low levels.
• Atrioventricular block: impaired electrical conduction.
• Bronchospasm: difficulty breathing, particularly in asthmatic patients.
• Hypotension: marked drop in blood pressure causing faintness.
• Allergic reactions: rash, itching, or swelling.
• Hepatic dysfunction: abnormal liver enzyme elevations.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Heart rate monitoring: assess baseline and periodic pulse.
• Hepatic impairment: use with caution in severe liver disease.
• Asthma or COPD: avoid in patients with active bronchospasm.
• Abrupt discontinuation: taper to prevent rebound hypertension.
• Renal function: adjust if severe renal insufficiency is present.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Other β‑blockers: additive bradycardia and hypotension.
• Calcium‑channel blockers (verapamil, diltiazem): enhanced negative chronotropic effect.
• Clonidine: may cause severe hypertension if stopped abruptly.
• Insulin or oral hypoglycemics: mask hypoglycemia symptoms.
• NSAIDs: may reduce antihypertensive effect.

Moderate Interactions (Monitor Closely)

• ACE inhibitors or ARBs: monitor for excessive blood‑pressure lowering.
• Diuretics: watch for electrolyte disturbances.
• Antidepressants (SSRIs, SNRIs): possible additive effects on blood pressure.
• Antiarrhythmic agents: potential for conduction abnormalities.
• CYP2D6 inhibitors (e.g., fluoxetine): may increase nebivolol plasma levels.